A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity.
Synan A, Wu NC, Velazquez R, Gesner T, Logel C, Mueller K, Green A, Barzaghi-Rinaudo P, Simmons Q, Mercan S, Shi X, Li X, Sagar V, Korn J, McLaughlin M, Tschantz WR, Hainzl D, Malamas A, Huber T, Cebe R, Xie KT, D'Alessio JA.
Synan A, et al. Among authors: wu nc.
MAbs. 2025 Dec;17(1):2441411. doi: 10.1080/19420862.2024.2441411. Epub 2025 Jan 6.
MAbs. 2025.
PMID: 39762718
Free article.